Kairos Pharma Ltd. (NYSE American: KAPA) has been named a winner in the 2026 GHP Magazine Healthcare & Pharmaceutical Awards, receiving recognition as the USA leader in drug resistance development. The award underscores the company's focus on advancing cancer therapeutics designed to address treatment resistance, a critical challenge in oncology.
The award highlights Kairos Pharma's work in extending the effectiveness of existing cancer therapies through innovative approaches that target drug resistance. According to the company, its lead candidate, ENV-105, is an antibody that targets CD105—a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 aims to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types.
Currently, ENV-105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer, addressing significant unmet medical needs. The company notes that as of the date of the press release, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any other comparable foreign regulator.
Kairos Pharma, based in Los Angeles, California, is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. The recognition from GHP Magazine underscores the potential impact of Kairos Pharma's research on improving outcomes for patients with treatment-resistant cancers.
The full press release regarding the award is available at https://ibn.fm/WuBOf. For more information about Kairos Pharma and its latest updates, visit their newsroom at https://ibn.fm/KAPA.
